335,541 Shares in AtriCure, Inc. $ATRC Purchased by Connor Clark & Lunn Investment Management Ltd.

Key Points

• Connor Clark & Lunn Investment Management acquired 335,541 AtriCure shares worth approximately $9.4 million, taking a 0.66% stake. Institutional investors collectively own 99.11% of the company.
• AtriCure reported quarterly EPS of $0.18 and revenue of $153.6 million, exceeding analysts’ revenue estimate of $151.8 million; fiscal 2026 EPS guidance is $0.24–$0.32.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and a $48.62 price target, while insiders have sold 53,616 shares worth roughly $2.15 million over the past 90 days.

Connor Clark & Lunn Investment Management Ltd. acquired a new position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 335,541 shares of the medical device company's stock, valued at approximately $9,388,000. Connor Clark & Lunn Investment Management Ltd. owned 0.66% of AtriCure as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ATRC. BlackRock Inc. bought a new position in shares of AtriCure during the 2nd quarter valued at approximately $125,198,000. Marshall Wace LLP raised its holdings in shares of AtriCure by 63.4% in the 4th quarter. Marshall Wace LLP now owns 913,453 shares of the medical device company's stock worth $36,136,000 after purchasing an additional 354,281 shares during the period. Wellington Management Group LLP lifted its stake in AtriCure by 8.1% in the third quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company's stock valued at $151,296,000 after purchasing an additional 322,818 shares during the last quarter. First Light Asset Management LLC lifted its stake in AtriCure by 32.0% in the fourth quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company's stock valued at $46,501,000 after purchasing an additional 285,083 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new position in AtriCure during the first quarter valued at $7,922,000. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at AtriCure

In other news, insider Karl S. Dahlquist sold 9,370 shares of the stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $48.89, for a total value of $458,099.30. Following the sale, the insider directly owned 87,319 shares of the company's stock, valued at approximately $4,269,025.91. This represents a 9.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Karen Prange sold 3,564 shares of the firm's stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total transaction of $138,283.20. Following the completion of the transaction, the director owned 22,809 shares of the company's stock, valued at $884,989.20. This trade represents a 13.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 53,616 shares of company stock worth $2,149,994. 4.00% of the stock is owned by corporate insiders.

AtriCure Price Performance

AtriCure stock opened at $48.17 on Thursday. The firm has a market capitalization of $2.45 billion, a P/E ratio of 229.39 and a beta of 1.20. AtriCure, Inc. has a one year low of $25.36 and a one year high of $49.88. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. The business has a fifty day moving average price of $37.09 and a 200-day moving average price of $32.06.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The company had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period in the previous year, the company posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities research analysts forecast that AtriCure, Inc. will post 0.2 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ATRC shares. Citigroup reissued a "market outperform" rating on shares of AtriCure in a research report on Tuesday, July 21st. UBS Group decreased their price objective on AtriCure from $55.00 to $50.00 and set a "buy" rating for the company in a report on Tuesday, July 28th. BTIG Research upped their price objective on shares of AtriCure from $45.00 to $55.00 and gave the company a "buy" rating in a report on Monday. Canaccord Genuity Group lifted their target price on shares of AtriCure from $53.00 to $55.00 and gave the stock a "buy" rating in a research note on Wednesday, May 6th. Finally, Wall Street Zen lowered shares of AtriCure from a "strong-buy" rating to a "buy" rating in a research report on Saturday, May 2nd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $48.62.

AtriCure Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source